Drugmaker paying $100M to settle US probe on pricing

Irish drugmaker Mallinckrodt agreed to pay $100 million to settle allegations a subsidiary broke U.S. antitrust laws.

Questcor, which was acquired by Mallinckrodt in 2014, bought the rights to Acthar, a type of hormone-based drug used to treat infantile spasms as well as multiple sclerosis, in 2001.

Over time, according to the Federal Trade Commission, Questcor raised the price from $40 per vial to more than $34,000.

Read more from Reuters.